ZTS NYSE
Credit Risk of going bust: lower than 57% of companies Debt: 22.2% of company value Bonds: $301.2M held by 308 funds, 68 bp over Treasuries → details ▾
If the stock fell to about $1.76 (down 98%), Zoetis Inc. would be worth roughly what it owes.
Total debt $9.24B against a stock market value of $32.33B.
Distance to default 5.81 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $4.52B (short-term plus half of long-term), stock volatility 40.4%; Altman Z 4.73. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Parsippany, NJ 07054
US
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| PECK KRISTIN C | A-Award | 720 | — | 2026-10-09 |
| Esch Kevin | A-Award | 360 | — | 2026-10-09 |
| Driscoll Rimma | A-Award | 278 | — | 2026-10-09 |
| FULLER JULIE | A-Award | 368 | — | 2026-10-09 |
| Sarbaugh Keith | A-Award | 303 | — | 2026-10-09 |